Geode Capital Management
KRBP

Geode Capital Management’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

Geode Capital Management’s Portfolio KRBP Stock Details KRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,365
Closed -$7K – 4875
2022
Q4 		$7K Hold
1,365
– – ﹤0.01% 4871
2022
Q3 		$11K Hold
1,365
– – ﹤0.01% 4977
2022
Q2 		$17K Hold
1,365
– – ﹤0.01% 4949
2022
Q1 		$34K Hold
1,365
– – ﹤0.01% 4881
2021
Q4 		$62K Sell
1,365
-359
-21% -$24.5K ﹤0.01% 4824
2021
Q3 		$158K Buy
+1,724
New +$178K ﹤0.01% 4533

Other funds holding KRBP

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Geode Capital Management's KRBP Position: Q1 2023 in Review

Geode Capital Management sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q1 2023, closing a stake of 1,365 shares — an estimated $7K sold.

Geode Capital Management first reported a position in KRBP in Q3 2021 and held it in 6 quarters. The position peaked at $158K in Q3 2021. 7 funds tracked by Wall St. Rank hold KRBP as of Q1 2023.

  • Geode Capital Management reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Geode Capital Management sold 1,365 Kiromic BioPharma, Inc. Common Stock shares in Q1 2023, an estimated $7K.
  • Geode Capital Management first reported a position in Kiromic BioPharma, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
  • Geode Capital Management's Kiromic BioPharma, Inc. Common Stock position peaked at $158K in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q1 2023.

Based on Geode Capital Management's 13F filing for Q1 2023, filed 15 May 2023.